Home » News » News

Categorie: News

Kidney Week 2017

The international kidney week is right around the corner. From 31 October until 5 November 2017 more than 13.000 kidney professionals from across the globe will come to New Orleans to exchange knowledge about the fight against kidney disease. Acute kidney injury (AKI) is one of the topics and this is also the main focus for one of our SUL compounds.

Sulfateq has developed and patented several unique and potent compounds that form a novel drug class protecting cells from various injuries. The intended use for one of these compounds, SUL-138, is the medical need Acute Kidney Injury (AKI) which is a complication for patients who undergo an of open-heart surgery. AKI effects at least 1.5 million patients a year. Our SUL-138 compound offers a prophylactic treatment for this patient group. Click on this link to read all about the prevention AKI by using our compound.

Do you want more information about our compounds or do you want to discuss possibilities? Please contact us, we are happy to hear from you!

New publication SUL-121 compound

In the range of compounds for protecting organs from Sulfateq a new paper is published.

We are proud to announce that Dr. L.E. (Leo) Deelman (UMCG) has published his paper on the protective effects of our SUL-121 compound in diabetes. SUL-121 preserves endothelial function and inhibits progression of kidney damage in type 2 diabetes mellitus in mice. In other words, SUL-121 is a compound that protects organs and blood vessels (it prevents the vessels from narrowing) in mice with diabetes. This is potentially very interesting for applications in diabetes and surgery.

SUL-121 provides two major benefits. The first is the attenuated progression of albuminuria and the limited extent of diabetes related renal damage in the db/db model of T2DM. Secondly, SUL-121 inhibited the development of endothelial dysfunction and normalized systemic ROS formation, which was supported by in-vitro experiments.

This is a next Proof of Concept of our SUL compounds, this time in a mouse model. Earlier the SUL-compound was already successful in a hamster model.

You can download the paper through this link, please share your thoughts with us.

Dr. Rob Henning on hibernation (BBC2)

Tonight (11 September 2017) please tune in to BBC2. At 22:00 (Dutch time), Professor Rob Henning of the UMCG discusses the need for human hibernation. In this episode of “The search for a new world” Christophe meets anaesthesiologist Dr. Rob Henning, who believes hibernating bears may hold the key to protecting the human body from the hazards of space. Sulfateq is proud to have Dr. Henning on board for the developments of our SUL-compounds.

For more information take a look on the official website of BBC2:

http://www.bbc.co.uk/programmes/b0953y04

Sepsis: a new application for the SUL-compounds?

Sulfateq B.V. is dedicated to developing new drugs for several diseases: Acute Kidney Injury (AKI), Chronic Obstructive Pulmonary Disease (COPD),  Type II Diabetes (T2D) and obesity. We can now proudly announce that the SUL-compounds are being tested in sepsis, which is a disease that is characterized by a life-threatening response of the host to an infection. The different immunological, neurological and physiological responses that occur result in organ failure. Current treatment of sepsis is limited to the symptomatic treatment by either antibiotics and or fluid drainage, so there is a need for an effective treatment.

The application of SUL-compounds in sepsis is being investigated by Dr. Hjalmar Bouma from the University Medical Centre Groningen (UMCG). Dr. Hjalmar Bouma is part of a special Sepsis research group that is currently investigating the effect of SUL-compounds in a mouse model for sepsis. He has been interviewed about sepsis and his study of the SUL-compounds. You can listen to this interview through this link (in Dutch). In addition, a sneak preview of this interview is already published. Note: both the interview and article are in Dutch.

BIO-Europe 2016 – Cologne

From 7 till 9 November 2016 we will be attending BIO-Europe 2016 in Cologne (Germany). BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. Our CEO Kees van der Graaf will be present on these days to talk about business opportunities.

Our main focus will be the prevention of Acute Kidney Injury with our SUL-138 compound. To advance the clinical trials we are looking for investors. Do you want to meet with Kees and discuss business? Please contact us.

More information about BIO-Europe can be found on the official BIO-Europe website.

Are you an investor and are you interested in our investment opportunities? Please click here!

The Sulfateq compound SUL-121 is proven to potentially contribute to the treatment of COPD

We are proud to announce that one of our SUL-compounds, SUL-121, is proven to have both an anti-inflammatory and bronchodilating effect in vitro and in vivo. In the study, performed by the University of Groningen, the researchers explored the anti-inflammatory and bronchodilating properties of the novel pharmacological compound SUL-121 in vitro and in vivo. Their conclusion is that SUL-121 can be a novel approach for treating the major burden disease COPD. The poster with the data were presented last May on the American Thorac Society (ATS2015) conference in Denver, Colorado.

COPD is a worldwide growing major health issue
Chronic Obstructive Pulmonary Disease (COPD) is a major public health problem. According to the WHO COPD is an under-diagnosed, life threatening lung disease that may progressively lead to death. COPD is characterized by airway obstruction and chronic inflammation. Although most patients can be treated with (combinations of) bronchodilating agents and anti-inflammatory glucocorticosteroids, a subset of patients responds poorly to these drugs leading to increased hospitalizations.

A new class of chemicals with major potential
SUL-121 is one of the new class of chemicals based on the protective effects of nature’s hibernation mechanism that have been developed by Sulfateq. These so-called SUL-compounds show a great potential in therapeutic application for human medicine. The SUL-compounds have been tested in animal models with prove of concept for the protection of cells, tissues and organs. Sulfateq B.V. has not only identified applications of the SUL-compounds in Chronic Obstructive Pulmonary Disease (COPD), but also for Acute Kidney Injury (AKI) and Obesity/Diabetes II.

If you are interested in the applications of the SUL-compounds please visit our website.